SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as the price experiences volatility, prompting discussions about potential bottom levels and future price movements. Community members are debating whether this is a buying opportunity or a sign of further decline, with some expressing concerns about market manipulation and potential liquidations. Broader conversations include the impact of external factors and historical trends on Bitcoin's performance.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending downwards amidst Bitcoin's recent volatility, sparking debates about its correlation with BTC and potential risks. Community discussions range from concerns about margin calls and possible delisting to speculation on a potential bottom, with some traders eyeing a bounce while others foresee further declines. The stock's performance is closely tied to Bitcoin's price movements and Michael Saylor's strategy, leading to heightened uncertainty and a wide range of opinions.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending amidst broader crypto market volatility and ahead of an earnings report, with community members debating the influence of figures like Tom Lee and speculating about potential staking strategies. Discussions include unrealized losses, potential liquidations, and whether the stock is undervalued relative to its Ethereum holdings. Some traders express frustration and accuse key figures of misleading investors, while others see a buying opportunity amid the dip.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending amid volatility, with investors reacting to a UBS price target increase and broader market concerns. Community discussions revolve around whether the recent selloff presents a buying opportunity or signals an overbought condition, especially with Nvidia's earnings on the horizon. Sentiment is mixed as some anticipate a continued rally driven by AI memory demand, while others foresee a deeper correction.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community discusses the potential impact of newly launched ETFs and the upcoming ISO 20022 standard implementation, while also navigating overall market volatility and price fluctuations. Community debates center on whether XRP can decouple from Bitcoin's influence and realize its utility for payments and tokenization. Some traders express frustration with recent price action, while others remain optimistic about long-term potential, particularly with institutional adoption.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

HOOD is trending amidst a recent dip, sparking debates about oversold conditions and potential for a rebound. Community members are weighing bullish and bearish scenarios, influenced by factors like Bitcoin's performance and broader market trends. Some traders discuss strategies like buying the dip or selling covered calls, while others speculate on future price movements and potential impacts of upcoming economic data.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is trending following earnings, with community members pointing to strong revenue growth and a significant EPS beat. Despite positive results, some express concern about the overall market conditions and potential dilution, while others remain bullish, anticipating future upgrades and a rise in stock price. Discussions also revolve around institutional interest and comparisons to similar companies like Robinhood.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

$BOB is gaining attention as a token built on the $ICP blockchain, with the community drawing comparisons to an early-stage $BTC and highlighting its capped supply and upcoming halving event. Some community members are swapping $ICP for $BOB, citing its potential for higher gains and its role in driving network revenue for $ICP. Discussions also focus on its multi-chain availability and mining pool developments.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending due to positive sentiment surrounding the AI sector, fueled by strong earnings from key partner Nvidia and the anticipation of increased demand for AI infrastructure. Community members are discussing the potential for a short squeeze given the stock's oversold conditions and significant short interest, while also acknowledging the volatility and historical underperformance of the stock relative to its peers. Recent news of authorized chip exports to Saudi Arabia and the UAE further supports discussions around SMCI's growth potential within the expanding AI landscape.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is trending as traders assess mixed market signals, including Nvidia's performance and jobs data, leading to uncertainty. Community discussions revolve around potential market corrections and hedging strategies, with some noting the fund's reverse split and its impact on options. Overall, the community exhibits a cautious stance amid the conflicting economic indicators and AI speculation.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Stocks To Research - November 17th

Cidara Therapeutics, Danaher, argenex, Vertex Pharmaceuticals, and Abivax are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of...

Abivax (NASDAQ:ABVX) Sets New 12-Month High - Still a Buy?

Abivax (NASDAQ:ABVX) Hits New 12-Month High - Should You Buy...

Biotech Stocks To Keep An Eye On - November 16th

Cidara Therapeutics, Danaher, Vertex Pharmaceuticals, argenex, and Abivax are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of...

Biotech Stocks To Consider - November 14th

Cidara Therapeutics, Danaher, argenex, Vertex Pharmaceuticals, Abivax, Moderna, and United Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Abivax (NASDAQ:ABVX) Sees Strong Trading Volume - Still a Buy?

Abivax (NASDAQ:ABVX) Sees Strong Trading Volume - Time to Buy...

Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know

Abivax SA Sponsored ADR (ABVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are Medical Stocks Lagging  Abivax SA Sponsored ADR (ABVX) This Year?

Here is how Abivax SA Sponsored ADR (ABVX) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Abivax (NASDAQ:ABVX) Sets New 52-Week High - Should You Buy?

Abivax (NASDAQ:ABVX) Reaches New 52-Week High - Here's Why...

Shares of Paris, France-based Abivax SA (ABVX) spiked by over 400% in Wednesday's early premarket session following a positive late-stage readout from the clinical-stage biotech.On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/ABVX">Abivax stock</a> improved further into the ‘extremely bullish’ territory (98/100), with the message volume score spiking to a near-perfect “99,” suggesting ‘extremely high’ retail chatter.<figure class="image"><img style="aspect-ratio:626/56;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_23_at_4_32_00_AM_png_77d276515d.webp" alt="Screenshot 2025-07-23 at 4.32.00 AM.png" width="626" height="56"><figcaption>ABVX sentiment and message volume as of 4:30 a.m., July 23 | source: Stocktwits</figcaption></figure>The Abivax stock stream on the platform saw a nearly 260% increase in watcher count over the 24 hours leading up to late Tuesday. The 24-hour message volume change was 3,900%.The stock was among the top five trending tickers on Stocktwits early Wednesday.The frenzied retail activity followed the small-cap biotech's announcement of positive topline results from two Phase 3 studies evaluating its obefazimod in adult patients with moderately to severely active ulcerative colitis (UC).Abivax evaluated a 50 mg once-daily oral dose of obefazimod, its lead candidate, in studies dubbed ABTECT 1 and ABTECT 2. The drug candidate demonstrated a placebo-adjusted remission rate of 19.3% in the first study and 13.4% in the second study.It also met all key secondary endpoints, demonstrating “highly statistically significant and clinically meaningful benefits.”The company said an ABTECT Maintenance trial is ongoing, with topline results expected in the second quarter of 2026. It added that out of the 1,275 patients randomized in the induction trials, 678 achieved a clinical response and were enrolled in part 1 of the maintenance trial.Abivax CEO Marc de Garidel said, “The strength of these results reinforces our belief in obefazimod, our first-in-class miR-124 enhancer, and its potential to become a transformative new treatment modality for patients with UC.”Contingent upon the 44-week maintenance trial producing successful results, the company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.Abiva engages in the development of therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.A bullish Stocktwits watcher flagged a potential move toward the $60-$80 level on Wednesday.<stembedurl>https://stocktwits.com/europetradefuture/message/622045234</stembedurl>Another user, who identified themselves as a UC patient, said, “The addressable market is huge and physicians are always looking for another treatment option aside from TNFs, JAKs, interleukins, etc — some of the biggest blockbuster drugs currently treat UC/Crohns.”<stembedurl>https://stocktwits.com/Jblack500/message/622027325</stembedurl>Abivax stock is up over 36.5% for the year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/south-korean-feels-the-heat-after-japan-inks-trump-trade-deal-officials-in-dc/ch8wK2GR5M7">South Korea Feels The Heat After Japan Inks Trump Trade Deal — Officials In DC To Salvage Terms Before August Deadline</a>

Artwork based on an endoscopic image of the colon affected by ulcerative colitis (Photo Courtesy of Juan Gartner via Getty Images)

Small-Cap Abivax Spikes 400% On Positive Late-Stage Ulcerative Colitis Drug Trial Results  — Retail Buzz Builds Around Blockbuster Potential

The drug candidate demonstrated a placebo-adjusted remission rate of 19.3% in the first study and 13.4% in the second study.

Equity

US-listed Abivax shares skyrocket on positive phase 3 data for colitis drug

Investing.com-- U.S.-listed shares of French biotech firm  Abivax SA  (EPA:ABVX) (NASDAQ:ABVX) skyrocketed in post-market trading on Tuesday after the company reported strong results from late-stage trials of its oral ulcerative colitis treatment, obefazimod.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Current Price	$122.90
Prev Close	$112.95
Open	$116.74
Dividend Yield	0.00%
50-Day Moving Average	$93.93
Beta	0.80
Avg. Volume	1.09M
PE Ratio	-40.64

52-Week High	$126.99
52-Week Low	$4.77
Market Capitalization	$9.57B
EPS (Annual)	-$3.02
Price to Book	-137.64
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ABVX
Abivax - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABVX News

ABVXAbivax - ADR